Quest for the right Drug

|
עמוד הבית / אודנטרון / מידע מעלון לרופא

אודנטרון ODNATRON (ONDANSETRON AS HYDROCHLORIDE DIHYDRATE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תוך-ורידי, תוך-שרירי : I.V, I.M

צורת מינון:

תמיסה להזרקה : SOLUTION FOR INJECTION

Pharmaceutical particulars : מידע רוקחי

6.       Pharmaceutical Particulars
6.1.      List of Excipients

Sodium chloride, citric acid monohydrate, sodium citrate, water for injection.

6.2.      Incompatibilities
Odnatron injection should not be administered in the same syringe or infusion as any other medication. Ondansetron injection should only be mixed with those infusion solutions that are recommended.

6.3.     Shelf Life
The expiry date of the product is indicated on the packaging materials.
After dilution: 24 hours (diluted with infusion fluids and stored at 2-8oC) 

6.4.      Special Precautions for Storage
Protect from light. Store below 250C.


6.5.      Nature and Contents of Container
Type I clear glass ampoules.

5 ampoules of 2 ml or 4 ml are packed in a carton.
Not all pack sizes may be marketed

6.6.      Special precautions for disposal and other handling
Odnatron Injection should not be autoclaved.
Compatibility with intravenous fluids
Odnatron injection should only be mixed with those infusion solutions which are recommended: 
•   Sodium Chloride Intravenous Infusion BP 0.9%w/v
•   Glucose Intravenous Infusion BP 5%w/v
•   Mannitol Intravenous Infusion BP 10%w/v
•   Ringers Intravenous Infusion
•   Potassium Chloride 0.3%w/v and Sodium Chloride 0.9%w/v Intravenous Infusion BP •    Potassium Chloride 0.3%w/v and Glucose 5%w/v Intravenous Infusion BP In keeping with good pharmaceutical practice dilutions of Odnatron injection in intravenous fluids should be prepared at the time of infusion or stored at 2-8 oC for no more than 24 hours before the start of administration.

Compatibility studies have been undertaken in polyvinyl chloride infusion bags and polyvinyl chloride administration sets. It is considered that adequate stability would also be conferred by the use of polyethylene infusion bags or Type 1 glass bottles. Dilutions of ondansetron in sodium chloride 0.9%w/v or in glucose 5%w/v have been demonstrated to be stable in polypropylene syringes. It is considered that Odnatron injection diluted with other compatible infusion fluids would be stable in polypropylene syringes.

Compatibility with other drugs: Odnatron may be administered by intravenous infusion at 1mg/hour, e.g. from an infusion bag or syringe pump. The following drugs may be administered via the Y-site of the Odnatron giving set for ondansetron concentrations of 16 to 160 micrograms/mL (e.g. 8 mg/500 mL and 8 mg/50 mL respectively);

Cisplatin: Concentrations up to 0.48 mg/mL (e.g. 240 mg in 500 mL) administered over one to eight hours.

5-Fluorouracil: Concentrations up to 0.8 mg/mL (e.g. 2.4g in 3 liters or 400 mg in 500 mL) administered at a rate of at least 20 mL per hour (500 mL per 24 hours). Higher concentrations of 5- fluorouracil may cause precipitation of ondansetron. The 5-fluorouracil infusion may contain up to 0.045%w/v magnesium chloride in addition to other excipients shown to be compatible.

Carboplatin: Concentrations in the range 0.18 mg/mL to 9.9 mg/mL (e.g. 90 mg in 500 mL to 990 mg in 100 mL), administered over ten minutes to one hour.

Etoposide: Concentrations in the range 0.14 mg/mL to 0.25 mg/mL (e.g. 72 mg in 500 mL to 250 mg in 1 liter), administered over thirty minutes to one hour.

Ceftazidime: Doses in the range 250 mg to 2000 mg reconstituted with Water for Injections BP as recommended by the manufacturer (e.g. 2.5 mL for 250 mg and 10 mL for 2g ceftazidime) and given as an intravenous bolus injection over approximately five minutes.

Cyclophosphamide: Doses in the range 100 mg to 1g, reconstituted with Water for Injections BP, 5 mL per 100 mg cyclophosphamide, as recommended by the manufacturer and given as an intravenous bolus injection over approximately five minutes.

Doxorubicin: Doses in the range 10-100 mg reconstituted with Water for Injections BP, 5 mL per 10 mg doxorubicin, as recommended by the manufacturer and given as an intravenous bolus injection over approximately 5 minutes.

Dexamethasone: Dexamethasone sodium phosphate 20mg may be administered as a slow intravenous injection over 2-5 minutes via the Y-site of an infusion set delivering 8 or 16mg of ondansetron diluted in 50-100 mL of a compatible infusion fluid over approximately 15 minutes.
Compatibility between dexamethasone sodium phosphate and ondansetron has been demonstrated supporting administration of these drugs through the same giving set resulting in concentrations in line of 32 microgram - 2.5mg/ mL for dexamethasone sodium phosphate and 8 microgram - 1mg/mL for ondansetron.
שימוש לפי פנקס קופ''ח כללית 1994 Nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. יירשם ע"י רופא אונקולוג לחולים אונקולוגיים בלבד
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

רישום

150 38 33805 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

20.12.21 - עלון לרופא 03.10.22 - עלון לרופא

עלון מידע לצרכן

15.05.18 - עלון לצרכן

לתרופה במאגר משרד הבריאות

אודנטרון

קישורים נוספים

RxList WebMD Drugs.com